The cost of Tagrisso (osimertinib) can vary significantly depending on factors such as geographic location, insurance coverage, and whether a patient is receiving it through a hospital or retail pharmacy. While a specific price is not universally fixed, the drug is generally considered to be expensive.
How much does Tagrisso cost without insurance?
Without insurance, the list price for a 30-day supply of Tagrisso can range from several thousand dollars. For example, one source indicates a list price of approximately $17,464 for a 30-day supply [1]. Patients should consult with their healthcare provider or a pharmaceutical assistance program for potential cost-saving options.
What financial assistance programs are available for Tagrisso?
AstraZeneca, the manufacturer of Tagrisso, offers several patient assistance programs. These programs may include co-pay assistance for eligible commercially insured patients, providing financial support to reduce out-of-pocket costs [2]. For uninsured or underinsured patients who meet certain criteria, free medication may be available through AstraZeneca's patient savings programs [2]. Information on these programs is typically available through the drug's manufacturer website or by speaking with a healthcare provider.
What is the patent status and exclusivity for Tagrisso?
Tagrisso is protected by multiple patents. As of late 2023, DrugPatentWatch.com indicates that there are numerous patents covering Tagrisso, with varying expiry dates. Some core patents are expected to expire in the mid-2030s, while others may extend further [3]. Patent expiry dates are crucial as they signal when generic versions of the drug could potentially enter the market, which typically leads to lower prices.
When might generic versions of Tagrisso become available?
The availability of generic osimertinib will depend on the expiration of all relevant patents and any associated market exclusivity periods. Based on the patent information available, generic competition is not expected for several years, with potential entry points for some generics after 2030 [3].
How does Tagrisso's cost compare to other lung cancer treatments?
Tagrisso is a targeted therapy for EGFR-mutated non-small cell lung cancer, a specific type of cancer treatment. When compared to other advanced lung cancer therapies, particularly newer targeted agents and immunotherapies, Tagrisso's pricing is often in a similar range, reflecting the high cost of developing and manufacturing these specialized medications.
What are the long-term cost implications for patients on Tagrisso?
Given the chronic nature of treating some forms of lung cancer, the long-term cost of Tagrisso can be substantial for patients, even with insurance. Extended treatment durations mean ongoing co-pays and potential out-of-pocket expenses. Access to financial assistance and patient support programs becomes critical for ensuring continuous treatment for eligible individuals.
---
1. "Tagrisso Cost & Savings Programs." Tagrisso.com, https://www.tagrisso.com/cost-and-savings.
2. "Tagrisso (osimertinib) Patient Assistance Programs." AstraZeneca Access 360, https://www.astrazeneca-us.com/patients/access-360/tagrisso.
3. "Osimertinib Patent Information." DrugPatentWatch.com, https://drugpatentwatch.com/osimertinib.